公开(公告)号：EP1542664A2

公开(公告)日：2005-06-22

申请号：EP03788401.2

申请日：2003-08-13

申请人： Medical College Of Georgia Research Institute, Inc.

发明人： MARCUS, Dennis, Michael ,  CHU, Chung, Kwang

IPC分类号： A61K31/07

CPC分类号： A61K31/56 ,  A61K9/0019 ,  A61K31/015 ,  A61K31/07 ,  A61K31/12 ,  A61K31/35 ,  A61K31/40 ,  A61K31/405 ,  A61K31/44 ,  A61K31/497 ,  A61K47/54 ,  A61K47/551 ,  A61K47/555 ,  Y10S514/914

摘要： The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention include a new class of carotenoid-linked drugs to treat such blinding retinal disease such as age-related macular degeneration, retinoblastoma, and diabetic macular edema. For example, the present invention comprises a method for the treatment of a disorder of the eye comprising linking a therapeutic agent to a xanthophyll carotenoid to create a prodrug, and administering a therapeutically effective amount of the prodrug to an individual in need of treatment. Provided are prodrugs for treatment of retinoblastoma, cystoid macular edema (CME), exudative age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, or inflammatory disorders.